Systematic literature reviews of clinical trials have indicated that CBD is associated with somnolence (particularly when used with CLB), as well as decreased appetite, diarrhoea, and elevated liver enzymes, especially in conjunction with valproate [57–59]. The gene discussed is CLYBL; the disease is Coma.